A clinical trial involving COVID-19 patients hospitalized at UT Health San Antonio and University Health, among roughly 100 sites globally, found that a combination of the drugs baricitinib and remdesivir reduced time to recovery, according to results published Dec. 11 in the New England Journal of Medicine.
Six researchers from UT Health San Antonio and University Health are coauthors of the publication because of the San Antonio site’s sizable patient enrollment in the trial.
WHAT’S THE IMPACT
The Adaptive COVID-19 Treatment Trial 2, which compared the combination therapy versus remdesivir paired with an inactive placebo in hospitalized COVID-19 patients, was supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
Significantly, patients on high oxygen by nasal canula or receiving breathing assistance with a mask when they were enrolled in the study had a time to recovery of 10 days with combination treatment